Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Type
3.3. Snippet by Route of Administration
3.4. Snippet by Mode
3.5. Snippet by Distribution Channel
3.6. Snippet by Region

4. Dynamics
4.1. Impacting Factors
4.1.1. Driver
4.1.1.1. The increasing preference for OTC drugs for dyspepsia treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with the dyspepsia drugs
4.1.3. Opportunity
4.1.4. Impact Analysis

5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Functional Dyspepsia*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Organic Dyspepsia

8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.1.2. Market Attractiveness Index, By Drug Type
8.2. Proton Pump Inhibitors*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.2.1. Lansoprazole
8.2.2.2. Omeprazole
8.2.2.3. Esomeprazole
8.3. H-2-receptor Antagonists
8.3.1.1. Cimetidine
8.3.1.2. Famotidine
8.3.1.3. Nizatidine
8.4. Antacids
8.4.1.1. Calcium Carbonate
8.4.1.2. Loperamide
8.4.1.3. Simethicone
8.4.1.4. Sodium Bicarbonate
8.5. Antibiotics
8.5.1.1. Amoxicillin
8.5.1.2. Clarithromycin
8.5.1.3. Metronidazole
8.5.1.4. Tetracycline
8.6. Prokinetics
8.6.1.1. Bethanechol
8.6.1.2. Metoclopramide
8.7. Antidepressants

9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral

10. By Mode
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
10.1.2. Market Attractiveness Index, By Mode
10.2. Over the Counter*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Prescription

11. By Distribution Channel
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies

12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.8.1. U.S.
12.2.8.2. Canada
12.2.8.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.8.1. Germany
12.3.8.2. UK
12.3.8.3. France
12.3.8.4. Italy
12.3.8.5. Spain
12.3.8.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.8.1. Brazil
12.4.8.2. Argentina
12.4.8.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.8.1. China
12.5.8.2. India
12.5.8.3. Japan
12.5.8.4. Australia
12.5.8.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode
12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Takeda Pharmaceutical Company Limited.
14.1.1. Company Overview
14.1.2. Product Type Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Sanofi
14.3. Haleon plc.
14.4. Procter & Gamble
14.5. Abbott
14.6. Pfizer Inc.
14.7. Woodward Pharma Services LLC
14.8. Lannett Company, Inc.
14.9. ANI Pharmaceuticals, Inc.
14.10. Salix Pharmaceuticals, Inc
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us